Corporate Announcement: Japanese Approval of BRINSUPRI (Brensocatib) for Non‑Cystic Fibrosis Bronchiectasis
Insmed Incorporated has secured approval from Japan’s Ministry of Health, Labour and Welfare for its once‑daily oral therapy BRINSUPRI (brensocatib 25‑mg tablet). The approval extends the drug’s indication to Japanese patients aged 12 years and older, aligning Japan’s regulatory status with the United States and European approvals that already cover this age group.
Clinical Basis for Approval
The decision rests on robust evidence from the Phase 3 ASPEN study, a randomized, double‑blind, placebo‑controlled trial designed to evaluate brensocatib’s efficacy and safety in patients with non‑cystic fibrosis bronchiectasis (NCFB). Key outcomes include:
| Endpoint | Result |
|---|---|
| Primary: Reduction in pulmonary exacerbations over 52 weeks | Significant decrease versus placebo (rate ratio < 1, p < 0.05) |
| Secondary: Time to first exacerbation | Extended median time (HR < 1, p < 0.01) |
| Secondary: Proportion exacerbation‑free | Higher in the brensocatib arm (OR > 1, p < 0.01) |
| Pulmonary function: FEV₁ decline | Slower rate of decline in the 25‑mg group (Δ FEV₁ ≈ 0.15 L/year) |
The study’s design ensured that patients received standard care (including airway clearance techniques and antibiotics as clinically indicated) while the investigational product was added to the treatment regimen. The 52‑week duration allowed assessment of both short‑term and sustained benefits.
Mechanism of Action
Brensocatib is a selective, irreversible inhibitor of dipeptidyl peptidase‑4 (DPP‑4), an enzyme that activates neutrophil serine proteases, particularly neutrophil elastase (NE). NE contributes to mucus hypersecretion, epithelial injury, and extracellular matrix degradation—hallmarks of NCFB pathogenesis. By covalently modifying the catalytic serine of DPP‑4, brensocatib reduces NE activity systemically, thereby dampening chronic neutrophilic inflammation without compromising innate antimicrobial defenses.
This first‑in‑class approach offers several advantages:
- Targeted Modulation: Unlike broad‑spectrum anti‑inflammatories, DPP‑4 inhibition selectively curtails protease‑mediated tissue damage while preserving essential neutrophil functions such as chemotaxis and phagocytosis.
- Oral Bioavailability: A once‑daily tablet simplifies adherence, a critical factor in chronic respiratory disease management.
- Safety Profile: The Phase 3 data demonstrated a tolerability profile consistent with other DPP‑4 inhibitors, with the most frequent treatment‑emergent adverse events being mild respiratory infections, headache, and cough.
Regulatory Pathway and Global Strategy
The approval process in Japan mirrors the pathways taken in the United States and European Union. Insmed leveraged the conditional approval framework in Japan, which allows earlier access based on robust clinical evidence and a risk‑management plan. The company’s submission included:
- Comprehensive pharmacokinetic and pharmacodynamic data supporting the 25‑mg dose.
- A detailed post‑marketing surveillance plan addressing long‑term safety and effectiveness.
- Comparative safety data against standard-of-care antibiotic regimens for exacerbation prophylaxis.
This milestone fits within Insmed’s broader commercialization strategy, which seeks to position BRINSUPRI as a cornerstone therapy in the management of NCFB worldwide. By securing approval in Japan—a market with a sizeable cohort of bronchiectasis patients—the company is poised to expand its global supply chain and market share.
Economic and Clinical Implications
From a business perspective, the Japanese approval opens a new revenue stream in a high‑penetration respiratory disease market. It also provides an opportunity for real‑world evidence generation, which can inform pay‑or‑service negotiations and support pricing strategies.
Clinically, BRINSUPRI offers a novel therapeutic option that addresses a previously unmet need. The drug’s efficacy in reducing exacerbations and slowing lung function decline aligns with the goals of disease‑modifying therapy—an attractive proposition for both clinicians and payers seeking to reduce the long‑term burden of NCFB.
Conclusion
Insmed’s approval of BRINSUPRI in Japan underscores the drug’s proven clinical benefit and its potential to transform the therapeutic landscape for non‑cystic fibrosis bronchiectasis. The combination of a scientifically rational mechanism, robust Phase 3 evidence, and a favorable safety profile positions BRINSUPRI as a promising, first‑in‑class treatment that balances efficacy with patient convenience.
